TransMedics Group Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome, everyone, to the Jefferies Global Healthcare Conference in London. My name is Young Li, one of the med tech analysts on the team. Really pleased to be joined by management from TransMedics. We have the founder, President, and CEO, Waleed Hassanein, and also the recently appointed CFO, Fernando Araujo. Gentlemen, welcome, and thanks for coming to our conference.
Thank you, Young. We appreciate the invite. We're looking forward to it.
All right, great. Why don't we start off high level? I mean, your business is a pretty unique business in the organ transplant industry. You're the leader in livers and hearts, and then you have a very differentiated technology portfolio as well as business model. From your perspective, how defensive is the business model? Because we hear about competitors quite frequently. How real are the competitive threats?
That's an excellent question, Young. I think, as I've stated publicly before, transplant is becoming a crowded marketplace. We're very, very proud of that because TransMedics created this focus on organ transplantation. We think this is a good renaissance for the entire field. However, we also are very confident that we built a very defensible moat that is very, very difficult to replicate, very expensive to replicate, and it takes a long time to replicate. That's the multi-layer of the best technology in the field, surrounded with a very, very large NOP network on a national basis, vertical integration of transplant logistics, digitization of the transplant ecosystem, and more recently, offering donor and recipient coordination for major transplant programs. So, we've proven the model, we've proven the profitability of the model, the operations of the model, and we're now expanding that model into Europe.
We feel pretty confident in our ability to defend that business in face of technology. We are also not standing still. We are investing in a very, very deep pipeline of product innovation, service innovation, digital transformation to continue to keep ahead of the curve and ahead of the pace and drive innovation in the field.
Mm-hmm. All right, great. I guess the recent results were really strong. It was the strongest quarter ever, even if you exclude some of the PAD Aviation revenue. You were able to grow sequentially in a typically pretty tough seasonal 3Q. That hasn't happened over the past two years. I guess, what drove this really strong performance in that quarter, even though donor volumes were down like 6% in that quarter?
I think, Young, as I stated publicly, it's execution, it's the pipeline, primarily ENHANCE Part A was a major catalyst. It's our liver continuing to deliver the best results in the field. It's our NOP service. It's just the expansion of our service program into donor and recipient coordination. Europe generated significantly higher quarter. I would say the entire business really delivered Q3 in a good pace, and we expect that cadence to continue to go forward.
All right, great. When we do KOL checks, we don't get nearly as much pushback on the clinical utility and benefits of OCS. We hear a lot more sort of on the economic side, the higher costs of the products and services. How do your account reps or clinical reps handle those type of conversations, or what type of economic or clinical data do you cite to sort of push back on that?
I think our team get less of those economics pushback because you guys are talking to either generalist or few of the transplant program. Listen, the fundamental thing for TransMedics is we know for a fact we're delivering significant clinical value. For that, there is a premium pricing that has to be involved. We think the huge economic efficiency that we deliver through our NOP network, through our vertical integration of logistics, it's something that surgeon check or the field check doesn't really factor in. Our team knows all those details. For example, I give you one example. We're the only organ preservation technology company that don't charge a dime if the organ is not transplanted after it's being an OCS. Every other technology in the field, any of the competition, they charge full price.
These are the economic things that our team knows how to articulate with the center. Again, you don't need to listen to me describing that. Look at our print, and if the economics are really something that is a challenge for adoption, we wouldn't be able to generate the momentum we're generating in the business today.
Mm-hmm. Got it. I guess, are there still major U.S. transplant programs that don't use TransMedics much, or at all? What's holding them back, and what can you do to eventually convert them?
I think, listen, we're happy with where we are, but we obviously have higher aspiration, and we will continue to drive towards deeper adoption within existing transplant centers and expanding to new centers. I think every major transplant program is familiar with OCS, familiar with TransMedics, familiar with NOP, except for very, very few kind of single-digit number accounts. Again, our team is doing a good job in targeting these accounts. Some of these accounts we have to wait on and be patient because, again, we have a lot to focus on, and one account is not going to be the make or break for TransMedics. We're also expanding into Europe, so again, the team is doing a great job. We're going deeper into existing accounts, we're opening up new accounts, but we have to let the process take its time. We can't force it. All right, got it.
I guess a unique capability that you guys have is scheduled liver transplants. What percentage of TransMedics livers are done that way currently? Are surgeons able to perform two liver transplants in a day using your tech?
Absolutely. Two or more. I would say more than 80% of our livers are done in morning hour transplant. It is one of our most important value proposition that drove adoption in liver transplantation. We designed ENHANCE and DENOVO to give us the ability to prove that capabilities in heart and lung transplantation as well. Yes, many centers are doing more than one liver a day because of that capabilities of OCS, and really NOP, and having the team dedicated to managing the organ while our team managing the organ while the surgeon is doing another transplant case.
All right. There is a lot of positive trial updates and progress in the last quarter. The heart ENHANCE Part A trial that completed enrollment, 175 patients in September. In October, the FDA approved the continued access protocol to enroll an additional 90 patients. What are the drivers and the significance behind that decision, and how does it help approvals?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
